Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

2023386 citationsJournal Articlegreen Open Access

Authors

Edward V. Loftus · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Julián Panés · Inserm

Ana P. Lacerda · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Laurent Peyrin‐Biroulet · Université de Lorraine

Geert D’Haens · Inserm

Remo Panaccione · Inserm

Walter Reinisch

Abstract

Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease. (Funded by AbbVie; U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.).

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Autoimmune and Inflammatory Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 21, pp. 1966-1980

DOI: 10.1056/nejmoa2212728

Field-Weighted Citation Impact: 120.45